NASDAQ:LMAT - LeMaitre Vascular Stock Price, Price Target & More

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

LeMaitre Vascular announced a quarterly dividend on Monday, April 23rd. Stockholders of record on Tuesday, May 22nd will be given a dividend of $0.07 per share on Thursday, June 7th. This represents a $0.28 annualized dividend and a dividend yield of 0.86%. The ex-dividend date is Monday, May 21st. View LeMaitre Vascular's Dividend History.

LeMaitre Vascular announced that its Board of Directors has authorized a share buyback plan on Friday, July 28th 2017, which authorizes the company to repurchase $7,500,000.00 in outstanding shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its shares are undervalued.

LeMaitre Vascular Inc (NASDAQ:LMAT) released its quarterly earnings results on Wednesday, April, 25th. The medical instruments supplier reported $0.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by $0.02. The medical instruments supplier earned $25.99 million during the quarter, compared to analyst estimates of $26.42 million. LeMaitre Vascular had a return on equity of 16.66% and a net margin of 17.34%. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.16 earnings per share. View LeMaitre Vascular's Earnings History.

LeMaitre Vascular issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $1.05-1.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.98. The company issued revenue guidance of $106-109 million, compared to the consensus revenue estimate of $111.05 million.LeMaitre Vascular also updated its Q2 guidance to $0.41-0.43 EPS.

5 brokers have issued 1 year price targets for LeMaitre Vascular's stock. Their predictions range from $31.00 to $40.00. On average, they expect LeMaitre Vascular's stock price to reach $34.40 in the next twelve months. View Analyst Ratings for LeMaitre Vascular.

Some companies that are related to LeMaitre Vascular include Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Luminex (LMNX), Glaukos (GKOS), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), MiMedx Group (MDXG), K2M Group (KTWO), CryoLife (CRY), OraSure Technologies (OSUR), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD) and Cerus (CERS).

Media headlines about LMAT stock have trended positive on Saturday, Accern reports. Accern rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. LeMaitre Vascular earned a news sentiment score of 0.36 on Accern's scale. They also assigned headlines about the medical instruments supplier an impact score of 47.59 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

LeMaitre Vascular's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.08%), Dimensional Fund Advisors LP (5.20%), Epoch Investment Partners Inc. (3.99%), Thomson Horstmann & Bryant Inc. (1.78%), Allianz Asset Management GmbH (1.70%) and Allianz Asset Management GmbH (1.70%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

LMAT stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Federated Investors Inc. PA, Russell Investments Group Ltd., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Biondo Investment Advisors LLC, Fiera Capital Corp and Thomson Horstmann & Bryant Inc.. Company insiders that have sold LeMaitre Vascular company stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas and Peter R Gebauer. View Insider Buying and Selling for LeMaitre Vascular.

LMAT stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Sensato Investors LLC, King Luther Capital Management Corp, BlackRock Inc., WINTON GROUP Ltd, Epoch Investment Partners Inc., Campbell & CO Investment Adviser LLC and Dupont Capital Management Corp. View Insider Buying and Selling for LeMaitre Vascular.

Shares of LMAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LMAT stock can currently be purchased for approximately $32.51.

LeMaitre Vascular has a market capitalization of $638.27 million and generates $100.87 million in revenue each year. The medical instruments supplier earns $17.17 million in net income (profit) each year or $0.86 on an earnings per share basis. LeMaitre Vascular employs 423 workers across the globe.

LeMaitre Vascular's mailing address is 63 SECOND AVENUE, BURLINGTON MA, 01803. The medical instruments supplier can be reached via phone at 781-221-2266.